Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Linperlisib in R/R NKTCL
NCT06793956Phase 1Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sintilimab and linperlisib in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Sun Yat-sen University. Primary endpoints: Dose-Limiting Toxicity and Recommended Phase 2 Dose. Started Feb 2025; status: recruiting.
02
Drugs
sintilimablinperlisib
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT06793956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06793956.